Biotechnology

By Amanda Gardner HealthDay Reporters by Amanda Gardner healthday -Wed, Nov 24, 11: 47 h. HITTITES WEDNESDAY, 24 November HealthDay News)--Clinicians did remarkable avances Treaty blood cancers and bone marrow and blood stem cell greffes in recent years, significantly reduced risk of complications related to the treatment and deaths, a new study shows. Between in the early 1990s and 2007, there was a year that 41 percent in global risk died in an analysis of more than 2,500 patients treated in Fred Hutchinson Cancer Center in Seattle, a leader in the field of blood cancers and other malignancies. Find the two Fred Hutchinson Cancer Center, who conducted the study, diminue dramatic treatment side effects an organ damage. The study was published in November 24 New England Journal of medicine in '' We had made progress in enormous knowledge of this very complex process and all the results, "said Senior study author Dr. George McDonald, a gastroenterologist and Hutchinson and...

Amanda Gardner, HealthDay Reporter Amanda Gardner Reporter Wed Nov – 24 11: 47 pm ET healthday WEDNESDAY, November 24, HealthDay News)--made significant advances in treating Clinical blood cancers at an early stage with the bone marrow and blood stem cells of human origin in recent years, treatment-related complications and death risk to reduce considerably the present level of a new study shows. the 1990s, and 2007 was 41% reduction in between, in the event of death in the analysis of more than 2 500 patients in the Fred Hutchinson Cancer Center in Seattle, blood cancers-the market leader in the field and other malignancies are dealt with in General may present a risk to public health. Fred Hutchinson Cancer Center, researchers who carry out research, stated that the treatment of complications such as infection and dramatic decreases in body injury. A study was published in the New England Journal of Medicine Nov 24 problem "We've made a huge increase in a position to unders...

LOS ANGELES (Reuters) – a key trial Seattle Genetics tests with the patients antibodies targeting cancer n Hodgkin Lymphoma, it was found that more than a third of them achieved the complete remission of their cancer. The company also said it expects to produce drugs now, following the US regulatory authorities brentuximab vedotin (2) years from the date of the first quarter of patients either n Hodgkin Lymphoma or anaplastic large cell Lymphoma (ALCL) that have ceased responding to other therapies. The company had previously said it would take place in the first half of 2011, the consignment. "Our goal should be submitted in the first quarter of the year, and can be placed on the market of an accelerated review in 2011," Seattle Genetics CEO Siegall told Reuters the telephone Clay in the interview. The experiment to compare with another drug brentuximab vedotin, but similar patients full cancellation of the course is typically a single character, he said. The company is dev...